ES2074490T3 - Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. - Google Patents

Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.

Info

Publication number
ES2074490T3
ES2074490T3 ES90105405T ES90105405T ES2074490T3 ES 2074490 T3 ES2074490 T3 ES 2074490T3 ES 90105405 T ES90105405 T ES 90105405T ES 90105405 T ES90105405 T ES 90105405T ES 2074490 T3 ES2074490 T3 ES 2074490T3
Authority
ES
Spain
Prior art keywords
preparation
procedure
via intravenous
immunoglobin
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90105405T
Other languages
English (en)
Other versions
ES2074490T5 (es
Inventor
Norbert Dr Dipl-Chem Kothe
Dieter Dr Dipl-Chem Rudnick
Detlef Dr Dipl-Chem Piechaczek
Herwald Dr Klein
Detlef Dr Dipl-Biol Rohm
Michael Dr Dipl-Chem Kloft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Pharma GmbH
Original Assignee
Biotest Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8203787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074490(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest Pharma GmbH filed Critical Biotest Pharma GmbH
Publication of ES2074490T3 publication Critical patent/ES2074490T3/es
Application granted granted Critical
Publication of ES2074490T5 publication Critical patent/ES2074490T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

METODO Y ELABORACION DE UN PREPARADO G, QUE SOPORTA LA INMUNOGLOBINA INTRAVENENOSA, EL CUAL ESTA LIBRE DE GRUPOS, SUSTANCIAS VASOACTIVAS Y ENCIMAS PROTEOLITICAS Y ES APROPIADO PARA UN COLECTIVO DE PACIENTES, CONCRETAMENTE PARA LOS PACIENTES "INMUNOSUPRIMIDOS", QUE CONSTA DE UN MATERIAL DE SALIDA CON UN CONTENIDO G DE INMUNOGLOBINA, LIBRE DE FACTORES DE COAGULACION, CON UN TRATAMIENTO DE UN % DE VOLUMEN DE 0,4 A 1,5 DE ACIDOS DE OCTANO Y/O CON UNA CROMATOGRAFIA SIGUIENTE, ESPECIALMENTE, EN EL INTERCAMBIO DE CATIONES O ANIONES O DE UNA MATRIX DE CROMATOGRAFIA DE HIDROFOBEN.
ES90105405T 1990-03-22 1990-03-22 Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. Expired - Lifetime ES2074490T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90105405A EP0447585B2 (de) 1990-03-22 1990-03-22 Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates

Publications (2)

Publication Number Publication Date
ES2074490T3 true ES2074490T3 (es) 1995-09-16
ES2074490T5 ES2074490T5 (es) 2004-02-16

Family

ID=8203787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90105405T Expired - Lifetime ES2074490T5 (es) 1990-03-22 1990-03-22 Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.

Country Status (7)

Country Link
US (1) US5164487A (es)
EP (1) EP0447585B2 (es)
JP (1) JPH06107561A (es)
AT (1) ATE122054T1 (es)
DE (1) DE59009020D1 (es)
DK (1) DK0447585T4 (es)
ES (1) ES2074490T5 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
DE19904407C2 (de) 1999-02-04 2001-09-20 Bayer Ag Vorrichtung zum Wechseln einer Düsenplatte eines Prillturmes und Verfahren zum automatisierten Wechsel
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
TWI320788B (en) * 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
JP5732196B2 (ja) * 2006-11-01 2015-06-10 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 低ｐＨおよび二価カチオンを用いる生物高分子を単離する方法
CN101679509A (zh) 2007-06-01 2010-03-24 弗·哈夫曼-拉罗切有限公司 免疫球蛋白纯化
AU2009236305B2 (en) 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
AU2009236653B2 (en) * 2008-04-16 2014-09-25 Biogen Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
FR2974301B1 (fr) * 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
JP2016509068A (ja) * 2013-02-28 2016-03-24 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ クロマチン欠損細胞培養採取物からの抗体のクロマトグラフィー精製
CN105008384A (zh) * 2013-02-28 2015-10-28 新加坡科技研究局 在高电导率下在非离子性有机聚合物的存在下的蛋白质纯化
US10144774B2 (en) 2013-07-01 2018-12-04 Csl Behring Ag Method for purifying IgG
SG10201811186XA (en) 2013-10-18 2019-01-30 Novasep Process Purification of proteins
US20170044210A1 (en) 2014-04-30 2017-02-16 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
ES2988823T3 (es) 2014-12-03 2024-11-21 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
KR101657690B1 (ko) * 2015-06-05 2016-09-19 주식회사 녹십자홀딩스 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
EP0338229B1 (de) * 1988-04-19 1993-06-16 Biotest Pharma Gmbh Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
FR2632308B1 (fr) * 1988-06-07 1991-08-16 Fondation Nale Transfusion San Procede et installation de fractionnement en continu de proteines vegetales animales ou humaines
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process

Also Published As

Publication number Publication date
ATE122054T1 (de) 1995-05-15
JPH06107561A (ja) 1994-04-19
US5164487A (en) 1992-11-17
EP0447585B1 (de) 1995-05-03
DE59009020D1 (de) 1995-06-08
EP0447585A1 (de) 1991-09-25
DK0447585T3 (da) 1995-05-29
EP0447585B2 (de) 2003-05-07
DK0447585T4 (da) 2003-09-01
ES2074490T5 (es) 2004-02-16

Similar Documents

Publication Publication Date Title
ES2074490T3 (es) Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.
SE8504967D0 (sv) A pharmaceutical composition and a method of treating the body
DE19375061I2 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
ATE110578T1 (de) Von hydrogel angetriebene verabreichungsvorrichtung.
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
KR900701261A (ko) 비만증 치료방법
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
DK0457849T3 (da) Klæbemiddel til elektrotransport
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ES2067624T3 (es) Un procedimiento de preparacion de una composicion farmaceutica liquida para administracion nasal.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
BR9201718A (pt) Concentrado de fator xi da coagulacao sanguinea de alta atividade especifica,apropriado para uso terapeutico e seu processo de preparacao
MX9203374A (es) Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina.
JO1619B1 (en) Contrast media
PT95212A (pt) Processo para a preparacao de uma composicao para uso topico para o tratamento da fragilidade capilar, contendo defibrotide
ES2055761T3 (es) Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.
ES2093811T3 (es) Medicamento que contiene proteina c.
DE69115687D1 (de) Verwendung von spezifischen Fettsäuren zur Herstellung eines Medikaments zur Verabreichung durch Iontophorese
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
IT8748117A0 (it) Derivati di glicina quali agenti preventivi e terapeutici per le complicanze diabetiche
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
ATE244011T1 (de) Unterdrückung der thromboxanspiegel durch perkutane verabreichung von aspirin
AU2525488A (en) Use of metalloporphyrins to reverse the toxic effect of tumor therapy
MX9201825A (es) Composicion farmaceutica que contiene calcitonina.
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 447585

Country of ref document: ES